Analytical Data
-
基因名
PSMA2
- Application
-
别名
PSMA2;HC3;PSC3;Proteasome subunit alpha type-2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P25787
-
表达区间
1 -234aa
-
氨基酸序列
MGSSHHHHHH SSGLVPRGSH MAERGYSFSL TTFSPSGKLV QIEYALAAVA GGAPSVGIKA ANGVVLATEK KQKSILYDER SVHKVEPITK HIGLVYSGMG PDYRVLVHRA RKLAQQYYLV YQEPIPTAQL VQRVASVMQE YTQSGGVRPF GVSLLICGWN EGRPYLFQSD PSGAYFAWKA TAMGKNYVNG KTFLEKRYNE DLELEDAIHT AILTLKESFE GQMTEDNIEV GICNEAGFRR LTPTEVKDYL AAIA
-
分子量
28 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The PSMA2 protein, a crucial component of the proteasome complex, plays a significant role in cellular protein degradation and regulation of various biological processes, including cell cycle progression and apoptosis. As a member of the 26S proteasome, which is responsible for the ubiquitin-proteasome pathway, PSMA2 is vital for maintaining cellular homeostasis and protein turnover. Recent studies have highlighted its implications in cancer biology, as dysregulation of the proteasome can lead to the accumulation of oncoproteins and decreased turnover of tumor suppressors. This has prompted research into PSMA2 as a potential therapeutic target, particularly in cancers where proteasome activity is enhanced. Furthermore, understanding the structural and functional intricacies of PSMA2 could provide insights into novel inhibitors that selectively disrupt its activity in malignant cells while sparing normal tissues. As a result, exploring the recombinant expression of PSMA2 not only holds promise for advancing our comprehension of proteasome functionality but also for developing targeted cancer therapies that could improve treatment outcomes. Overall, the research into PSMA2 and its recombinant forms is at the forefront of efforts to harness the proteasome's role in disease modulation and therapeutic intervention.
